Jul. 3 at 5:16 PM
After a 15.7% drop post-earnings,
$ELTP is bouncing back! 📈
Revenues surged by 48.4% year-over-year to
$84M in FY2025, thanks to robust generic sales and a strong debut of its lisdexamfetamine line. Despite a pretax loss due to a non-cash expense impacting net results, operational performance remained robust.
Discover ELTP's growth potential and strategic moves here 👉 https://www.zacks.com/commentary/2562093/elite-pharmaceuticals-stock-dips-despite-record-fy25-revenue-jump?cid=sm-stocktwits-2-2562093-body-768&ADID=SYND_STOCKTWITS_TWEET_2_2562093_BODY_768